

Supplementary Information

Identification of the First Highly Selective inhibitor of Human Lactate

Dehydrogenase B

Sachio Shibata^{1+*}, Satoshi Sogabe^{1#}, Masanori Miwa¹, Takuya Fujimoto², Nobuyuki Takakura², Akihiko Naotsuka¹, Shuji Kitamura², Tomohiro Kawamoto^{1*}, and Tomoyoshi Soga³

Supplemental Data includes:

Supplementary Figure 1. Linearity of MS-based NADH and NAD⁺ detection.

Supplementary Figure 2. Determination of LDHB and LDHA assay conditions.

Supplementary Figure 3. Nonlinear fits of the Michaelis–Menten kinetics for LDHB in the presence of AXKO-0046.

Supplementary Figure 4. Time-dependency inhibition of LDHB activity by AXKO-0046.

Supplementary Figure 5. The Fobs–Fcalc electron density omit maps of the quarterly complex contoured at 3 σ

Supplementary Figure 6. Superposition of eight monomers in the asymmetric unit of the LDHB/NADH complex.

Supplementary Figure 7. Comparison of the root-mean-square deviation values per amino-acid residue of LDHB between the two complexes.


Supplementary Figure 8. Sequence alignment of human LDHA and human LDHB.

Supplementary Figure 9. Structural comparison between the allosteric site of LDHB and that of LDHA (PDB code 4OKN).

Supplementary Table 1. Selectivity profile of the LDHB hit compound.


Supplementary Table 2. Inhibitory activity of LDHB by AXKO-0046 at varying concentrations of NADH and pyruvate.

Supplementary Table 3. Data collection and refinement statistics.




Supplementary Figure 1. Linearity of MS-based NADH and NAD⁺ detection.

Linearity were detected up to 100 μM NADH, **a** (closed circles) and NAD⁺, **b** (open circles) with a limit of detection at 0.78 μM using the RF-MS assay. Linearity is shown as insets for lower concentrations of the analytes. Data shown are mean \pm standard deviation (SD) ($n=4$).




Supplementary Figure 2. Determination of LDHB and LDHA assay conditions.



a, d Initial velocities for LDHB with pyruvate (75 μ M) and NADH (75 μ M) determined using RapidFire MS. The LDHB or LDHA reaction (0.0625 to 0.5 nM) showed good linearity up to 20 min. The assay was performed with pyruvate (500 μ M) and increasing concentrations of NADH, **b, e** or NADH (500 μ M) and increasing concentrations of pyruvate **c, f**. Data were fitted to the Michaelis–Menten equations to obtain kinetic constants K_m using GraphPad Prism. Data are shown as the mean \pm standard deviation (SD) ($n=4$).




Supplementary Figure 3. Nonlinear fits of the Michaelis–Menten kinetics for LDHB in the presence of AXKO-0046. Michaelis-Menten Kinetics for LDHB were determined from the initial reaction velocities of **a** NADH and **b** pyruvate of varying substrate concentrations in the presence of the indicated concentration of AXKO-0046




Supplementary Figure 4. Time-dependency inhibition of LDHB activity by AXKO-0046. Time dependency inhibition was measured by preincubating AXKO-0046 and LDHB for 0, 30, 60 or 120 min as indicated before initiating the LDHB reaction. Data are shown as the mean ($n=2$).

a**b**

Supplementary Figure 5. The $F_{\text{obs}} - F_{\text{calc}}$ electron density omit maps of the quarterly complex contoured at 3σ : a NADH and oxamate and b AXKO-0046.



Supplementary Figure 6. Superposition of eight monomers in the asymmetric unit of the LDHB/NADH complex. The active-site loop (residues Glu101–Leu110) is in magenta.




Supplementary Figure 7. Comparison of the root-mean-square deviation values per amino-acid residue of LDHB between the two complexes. RMSD was calculated from the sets of aligned conformations.

LDHA	1	MATLK	DQLIY	NLLKEEQ	T-P	QNKITVVG	VG	AVGMA	CAISI	LMKD	LADELA	LVDVI	EDK	LK	59				
LDHB	1	MATLK	EKLIA	PVAEE	EATVP	NNKITVVG	VG	QVGMA	CAISI	LGKS	LADELA	LVDVL	EDK	LK	60				
LDHA	60	GEMMDLQHG	S	LFLR	TPKIV	S	GKDY	NVTANS	KLVI	I	TAGAR	QQEGES	RNLN	VQRNV	NI	FKF	119		
LDHB	61	GEMMDLQHG	S	LFLQ	TPKIV	A	DKDY	S	V	TANS	KI	VVV	TAGVR	QQEGES	RNLN	VQRNV	NV	FKF	120
LDHA	120	IIPNV	VKYSP	NCKLLI	VSNP	VDILTY	V	AWK	ISGF	P	KNRVI	GSGCN	LDSAR	FRYLM	G	ER	LG	179	
LDHB	121	IIPQI	VKYSP	DCIII	VSNP	VDILTY	V	TWK	LSGL	P	KHRVI	GSGCN	LDSAR	FRYLM	A	E	LG	180	
LDHA	180	VHPL	SCHGW	V	LGEHGD	SSVP	VWSGM	NVAGV	SLKT	L	HPDLG	TDKDK	EQWKE	VHKQ	V	VESAY	239		
LDHB	181	IHP	SCHGW	I	LGEHGD	SSVA	VW	SGV	NVAGV	SLQ	L	NPEMG	TDNDS	E	NWKE	VHKM	V	VESAY	240
LDHA	240	EVIKL	KGYTS	WAIGLS	VADL	AESIM	KNLR	R	VHPV	STM	IKG	LYGI	KDDV	FL	SVPCIL	GQNG	299		
LDHB	241	EVIKL	KGYTN	WAIGLS	VADL	IESML	KNLSR	I	HPV	STM	VKG	MYGI	E	NEVFL	SLPCIL	NARG	300		
LDHA	300	ISDLV	KVT	L	T	SEEE	AR	LKKS	ADTLW	G	IQKE	LQ	-	F			332		
LDHB	301	LTSV	INQ	K	L	K	D	DEVA	Q	LKKS	ADTLW	D	I	QKD	L	KDL	334		

Supplementary Figure 8. Sequence alignment of human LDHA and human LDHB.

Residues depicted in Figure 5b are in red.



Supplementary Figure 9. Structural comparison between the allosteric site of LDHB and that of LDHA (PDB code 4OKN). Amino acid differences of both enzymes are labelled.

Supplementary Table 1. Selectivity profile of the LDHB hit compound.

ID	Deconvolution assay (% inhibition at 30 μM)	LDHB (IC ₅₀ , μM)	LDHA (IC ₅₀ , μM)	Ratio (LDHA (IC ₅₀) /LDHB (IC ₅₀))
AXKO-0001	50	23	12	0.5
AXKO-0002	95	5.6	<3	<0.5
AXKO-0003	50	33	71	2.2
AXKO-0004	45	15	>300	20.0
AXKO-0005	38	32	34	1.1
AXKO-0006	37	30	6.4	0.21
AXKO-0007	40	38	28	0.7
AXKO-0008	53	16	130	8.1
AXKO-0009	54	21	39	1.9
AXKO-0010	44	<3	>300	>100
AXKO-0011	59	17	22	1.3
AXKO-0012	53	8.1	6.8	0.8
AXKO-0013	84	5.5	30	5.5
AXKO-0014	67	15	77	5.1
AXKO-0015	51	30	130	4.3
AXKO-0016	55	13	19	1.5
AXKO-0017	60	22	24	1.1
AXKO-0018	92	6.7	<3	<0.4
AXKO-0019	49	27	36	1.3
AXKO-0020	78	9.5	22	2.3
AXKO-0021	53	20	63	3.2
AXKO-0022	34	15	39	3.2

Supplementary Table 2. Inhibitory activity of LDHB by AXKO-0046 at varying concentrations of NADH and pyruvate.

	NADH (μM)				
	10	30	50	100	200
IC ₅₀ (nM)	N.D.	702.1	329.5	223.0	94.2
	Pyruvate (μM)				
	10	30	50	100	200
IC ₅₀ (nM)	N.D.	197.1	114.2	223.0	96.3

Supplementary Table 3. Data collection and refinement statistics.

	LDHB/NADH/oxamate/AXKO-0046	LDHB/NADH
Data collection		
Space group	<i>P</i> 2 ₁	<i>C</i> 2
Unit cell dimensions a, b, c (Å), α , β , γ (°)	59.4, 137.6, 84.9, 90, 109.3, 90	232.5, 84.2, 156.2, 90, 120.8, 90
Resolution (Å)	50-1.55 (1.58-1.55)	50-1.80 (1.83-1.80)
Redundancy	4.1 (3.5)	3.4 (3.4)
Completeness (%)	99.2 (93.8)	99.6 (100.0)
<i>I</i> / σ	20.3 (4.0)	19.8 (2.1)
<i>R</i> _{sym}	0.076 (0.251)	0.065 (0.511)
<i>CC</i> _{1/2}	0.989 (0.923)	0.994 (0.736)
Refinement		
Resolution (Å)	50-1.55 (1.58-1.55)	50-1.80 (1.85-1.80)
No. reflections	174218 (12517)	225765 (17284)
<i>R</i> _{work} / <i>R</i> _{free}	0.170 (0.204) / 0.192 (0.233)	0.170 (0.238) / 0.203 (0.269)
No. atoms Protein / Ligand / Water	10253 / 284 / 765	20488 / 484 / 977
B-factors (Å ²) Protein / Ligand / Ion / Water	25.2 / 28.7 / 32.5	31.5 / 31.0 / 32.4
Rms deviation from ideal geometry Bond lengths (Å) / angles (°)	0.011 / 1.549	0.010 / 1.548
Ramachandran plot Preferred / Allowed / Outliers (%)	96.1 / 3.2 / 0.7	94.7 / 4.6 / 0.7
PDB code	7DBJ	7DBK

Values in parentheses indicate the highest-resolution shell.